阿达木单抗治疗 Vogt-小柳原田病患者眼部炎症加重或复发的疗效和安全性：一项多中心研究。
Efficacy and Safety of Adalimumab for Exacerbation or Relapse of Ocular Inflammation in Patients with Vogt-Koyanagi-Harada Disease: A Multicenter Study.
机构信息
Department of Ophthalmology, National Defense Medical College, Saitama, Japan.
Department of Ophthalmology, Tokyo Medical University, Tokyo, Japan.
出版信息
Ocul Immunol Inflamm. 2024 May;32(4):367-375. doi: 10.1080/09273948.2022.2092007. Epub 2022 Jun 24.
PURPOSE
We investigated efficacy and safety of adalimumab (ADA) treatment for exacerbation or recurrence of Vogt-Koyanagi-Harada (VKH) patients.
METHODS
Medical records of 70 VKH patients who received ADA treatment for more than 6 months were retrospectively investigated.
RESULTS
The mean age of VKH patients was 54.8 ± 15.1 years, and male/female ratio was 34/36, and sunset glow fundus was observed in 71.4%. Subfoveal choroidal thickness, indocyanine green angiography scores, and corticosteroid and cyclosporine doses were significantly reduced by ADA treatment for 6 months compared to baseline, while LogMAR and flare counts were also improved without being statistically significant. Adverse events were observed in 17.1%, in which tuberculosis was at 7.14% and psoriasis was at 2.86%; however, ADA treatment was continued in 91.4%.
CONCLUSIONS
ADA was shown to be effective to achieve remission of VKH disease refractory to conventional treatments and was generally well tolerated with few serious adverse events.
目的
我们研究了阿达木单抗（ADA）治疗 Vogt-小柳-原田（VKH）患者疾病加重或复发的疗效和安全性。
方法
回顾性调查了 70 例接受 ADA 治疗超过 6 个月的 VKH 患者的病历。
结果
VKH 患者的平均年龄为 54.8±15.1 岁，男女比例为 34/36，有 71.4%的患者出现落日眼征。与基线相比，ADA 治疗 6 个月后，患者的中心凹下脉络膜厚度、吲哚青绿血管造影评分以及皮质类固醇和环孢素剂量均显著降低，而 LogMAR 和光凝斑计数也有所改善，但无统计学意义。17.1%的患者出现不良反应，其中结核病占 7.14%，银屑病占 2.86%；然而，91.4%的患者继续接受 ADA 治疗。
结论
ADA 对常规治疗难治性 VKH 疾病有效，且通常具有良好的耐受性，仅有少数严重不良事件。
Zotero 插件